Glaucoma, Vision & Longevity: Supplements & Science

VisualFieldTest.com

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

  1. 1d ago

    Who Should Get Visual Field Testing? A Population-Based Framework

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/who-should-get-visual-field-testing-a-population-based-framework Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Who Should Get Visual Field Testing? A Population-Based Framework Visual field testing measures how well a person sees across the central and peripheral parts of the visual field. It is especially important because many eye and brain disorders damage peripheral vision gradually, without causing obvious symptoms at first. However, routine visual field testing is not necessary for every healthy, asymptomatic adult. The highest value comes from testing people whose examination, medical history, medication use, or disease pattern creates a meaningful risk of developing or worsening field loss. This targeted approach helps detect silent damage while limiting false-positive results, unnecessary anxiety, and avoidable testing. What Visual Field Testing Detects Most clinical visual field tests use automated static threshold perimetry. One eye is tested at a time while the patient looks at a central target and presses a button whenever a spot of light is seen. The test can identify: Peripheral blind spots caused by glaucoma Central or paracentral defects affecting reading or fixation Bitemporal defects associated with pituitary or other chiasmal disease Altitudinal defects associated with ischemic optic neuropathy Enlargement of the blind spot associated with papilledema Concentric peripheral loss caused by some toxic retinal disorders Hemifield loss after stroke or damage to the visual pathways Visual field testing is different from a visual acuity test. A person may still read the eye chart well while having important peripheral field loss. The two eyes also overlap, allowing one eye to compensate for defects in the other. Because visual field testing depends on attention, learning, fatigue, and response consistency, one abnormal result should usually be confirmed unless the pattern is clearly urgent. National Institute for Health and Care Excellence glaucoma guideline () The Population-Based Principle: Targeted Testing Rather Than Universal Screening The United States Preventive Services Task Force has found insufficient evidence to recommend routine population-wide screening for primary open-angle glaucoma in asymptomatic adults. This does not mean that visual field testing is unhelpful. Rather, it means that testing is more useful when directed toward people with identifiable risk factors or suspicious findings. United States Preventive Services Task Force recommendation () A comprehensive eye examination is still important, particularly as people get older or develop medical risk factors. The American Academy of Ophthalmology recommends a baseline comprehensive eye examination around age 40, with follow-up based on individual risk. Visual field testing should then be added when there is a suspicious optic nerve, elevated intraocular pressure, a relevant medication exposure, visual symptoms, or a disorder affecting the optic nerve or brain. American Academy of Ophthalmology glaucoma screening information () The groups most likely to benefit from routine or repeated testing are: Glaucoma suspects People with ocular hypertension People with established glaucoma Patients with neuro-ophthalmic disease Patients taking medications that can injure the retina or optic nerve Evidence on Asymptomatic Visual Field Loss Glaucoma may be advanced before a patient notices it Glaucoma usually develops slowly. Early defects often occur outside the central line of sight, and the brain can partially compensate for missing information. As a result, patients may not notice a problem until the disease is advanced. Population-based research has found that approximately half of people with manifest glaucoma in developed countries may be unaware that they have the disease. In a screening cohort from the Early Manifest Glaucoma Trial, one-third of people with previously undetected glaucoma had advanced visual field loss in at least one eye. Early Manifest Glaucoma Trial population screening study () The risk is not limited to people with poor visual acuity. A patient can have good central vision and still have loss in the upper, lower, nasal, or temporal field. Visual field loss has also been associated with reduced mobility, falls, and lower quality of life in population studies. Rotterdam Study of visual field loss and daily functioning () Why asymptomatic loss matters clinically Detecting field loss before a patient notices it can: Confirm that structural changes are functionally important Establish the stage of glaucoma Identify patients who need pressure-lowering treatment Reveal progression before a major daily-life problem develops Prompt neurological imaging when the pattern is not typical for glaucoma Trigger medication review when toxicity is suspected The goal is not simply to find an abnormal test. The goal is to find a repeatable, clinically meaningful change that alters care. Glaucoma Suspects A glaucoma suspect may have one or more of the following: Elevated intraocular pressure A large or asymmetric optic nerve cup Suspicious thinning of the retinal nerve fiber layer A disc hemorrhage A suspicious or borderline visual field A strong family history of glaucoma Thin central corneas Myopia, pseudoexfoliation, pigment dispersion, or other risk factors A person can be a glaucoma suspect even when the visual field is normal. In this situation, the field provides an important functional baseline against which later tests can be compared. Who among glaucoma suspects benefits most? Visual field testing is particularly valuable when a patient has: A suspicious optic nerve appearance Asymmetry between the two optic nerves Retinal nerve fiber layer or ganglion cell thinning on imaging Repeatedly elevated intraocular pressure A first-degree relative with glaucoma A disc hemorrhage A thin central cornea High myopia A previous borderline or abnormal field A visual complaint that is not explained by glasses, cataract, or retinal disease The American Academy of Ophthalmology recommends that observed primary open-angle glaucoma suspects generally be reassessed at least every 12 to 24 months, with more frequent assessment when several risk factors are present. American Academy of Ophthalmology Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern () How visual field results change care in a glaucoma suspect Normal and stable field: continued observation may be appropriate. One questionable abnormal field: repeat the test, check reliability, and compare it with the optic nerve and imaging. Repeatable glaucomatous pattern: the diagnosis may change from “suspect” to glaucoma. Field loss that does not match the optic nerve: consider a neurological or retinal cause. Paracentral loss: closer monitoring is often needed because central function may be threatened even when the overall field appears mild. A visual field should therefore be interpreted together with intraocular pressure, optic nerve examination, retinal imaging, corneal thickness, and the patient’s history. People With Ocular Hypertension Ocular hypertension means that the pressure inside the eye is consistently elevated, but there is not yet definite optic nerve damage or visual field loss. Many people with ocular hypertension never develop glaucoma. The Ocular Hypertension Treatment Study found that about 9.5% of untreated participants developed glaucoma over five years, compared with about 4.4% of participants who received pressure-lowering treatment. Risk was not equal among all participants. Higher pressure, older age, larger cup-to-disc ratio, and thinner central corneas increased the likelihood of conversion. American Academy of Ophthalmology EyeWiki: Ocular Hypertension () Why visual fields are still needed when the field is initially normal A normal field helps confirm that elevated pressure has not yet caused detectable functional damage. Repeated testing can later identify conversion from ocular hypertension to glaucoma. For a low-risk patient with normal optic nerves and stable pressure, visual field testing does not need to be performed at every visit. In contrast, a patient with very high pressure, a thin central cornea, a strong family history, older age, suspicious imaging, or a disc hemorrhage generally deserves closer surveillance. The National Institute for Health and Care Excellence recommends reassessment approximately every 18 to 24 months for treated ocular hypertension with controlled pressure and no detected conversion, but approximately every 6 to 12 months when conversion is uncertain or pressure control is inadequate. These intervals are guides rather than rigid rules. National Institute for Health and Care Excellence reassessment guidance () Practical approach for ocular hypertension A reasonable approach is: Obtain a reliable baseline visual field, often repeating it to confirm consistency. Document the optic nerve and retinal nerve fiber layer. Measure central corneal thickness. Estimate conversion risk using the full clinical picture. Repeat the field approximately every 12 to 24 months if risk is low and all findings remain stable. Test every 6 to 12 months when risk is moderate or high. Repeat sooner when pressure rises, the optic nerve changes, or a disc hemorrhage appears. Established Glaucoma Patients with established glaucoma benefit most consist Support the show

    Who Should Get Visual Field Testing? A Population-Based Framework

  2. 2d ago

    Real-World Evidence: Outcomes When Testing Frequency Increases

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/real-world-evidence-outcomes-when-testing-frequency-increases Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Real-World Evidence: Outcomes When Visual Field Testing Frequency Increases Visual field testing, also called perimetry, measures areas of vision that a person can and cannot see. It is especially important in glaucoma, because damage to the optic nerve may progress without noticeable symptoms until substantial vision has been lost. The practical question is not simply whether more tests produce more data. It is whether more frequent testing leads to earlier detection of true progression, better treatment decisions, preserved vision, and acceptable safety and workload. The current evidence suggests that increasing testing frequency usually improves the speed and precision of detecting visual field change. However, there is not yet strong proof that more frequent testing alone prevents blindness or improves quality of life. Evidence for home visual field testing used alongside clinic care is encouraging but still based mainly on small, selected studies rather than large comparative outcome trials. Key Findings at a Glance Clinic-based testing every six months detects progression earlier than approximately yearly testing, particularly when overall visual field trends are analyzed. In a large United States claims cohort, the median testing frequency was only 0.63 visual field tests per year, and more than three-quarters of patients had fewer than one test per year. Home testing can provide weekly or monthly measurements, reduce measurement noise, and sometimes identify a concerning change before the next planned clinic visit. Adherence is the main limitation. Short studies often report good participation, but longer studies show that testing frequency commonly declines over time. More frequent testing also produces more apparent progression signals, some of which later disappear. Confirmation rules are therefore essential. Direct evidence that increased testing changes long-term visual outcomes remains limited. Home testing should generally be treated as an adjunct to clinical examination, not a replacement for eye pressure measurement, optic nerve examination, imaging, and standard clinic-based perimetry. What Guidelines Recommend The European Glaucoma Society notes that there is still no definitive evidence showing which combination of tests or testing frequency produces the best patient outcomes at a sustainable cost. Nevertheless, it recommends obtaining enough early visual field measurements to estimate the individual rate of change. Newly diagnosed patients are often recommended to have standard automated perimetry approximately three times per year during the first two years, after which the schedule can be tailored to disease severity and observed progression. European Glaucoma Society guidelines The World Glaucoma Association similarly recommends an intensive early series in people at risk of visual disability. It suggests that lower-risk patients may later be tested about once a year, while higher-risk patients may need testing twice a year or more often if progression is suspected. World Glaucoma Association consensus These recommendations are based largely on the need to establish a reliable baseline and identify fast progression early. They should not be interpreted as a requirement for every patient to have the same schedule. Testing frequency should reflect: Existing visual field damage Rate of previous change Age and expected lifetime risk Whether the patient has only one useful eye Pressure control Optic nerve or retinal nerve fiber layer changes Presence of optic nerve hemorrhage Test reliability Patient ability to attend or complete testing How Often Are Patients Actually Tested? United States nationwide data A study of 380,029 people with open-angle glaucoma found that: 8.8% had no visual field test during the study period. 68.2% received fewer than 0.9 tests per year. Only 0.8% received at least 2.1 tests per year. The median testing frequency was 0.63 tests per year. The authors concluded that more than 75% of the population had fewer than one visual field test per year, which is below the frequency commonly recommended for many patients under active glaucoma monitoring. This study described healthcare delivery; it did not prove that increasing frequency would prevent vision loss. United States nationwide glaucoma cohort English hospital eye-service data A large electronic medical record audit evaluated 602,439 visual field records from 73,994 people across five glaucoma clinics in England. Among 25,760 patients with repeatable visual field loss: The median interval between visual field tests was 11.2 months. Approximately 4.6% of tests were classified as unreliable using the study’s reliability measure. The median rate of visual field change was approximately −0.21 decibels per year. About 24% of patients had advanced field loss at presentation. Differences in testing intervals and reliability were observed between clinics. This type of registry evidence is valuable because it reflects routine care rather than a highly controlled clinical trial. It also demonstrates how electronic records can monitor service quality, identify patients at risk, and measure whether a clinic is delivering testing consistently. English glaucoma visual field audit Outcomes When Clinic-Based Testing Frequency Increases Earlier detection of progression One of the clearest real-world analyses came from the Advanced Glaucoma Intervention Study. Researchers compared the original series of visual fields with a reduced-frequency series created by removing approximately every other follow-up test. The higher-frequency series had a median of 20 tests, compared with 12 tests in the lower-frequency series. Using a global measure called mean deviation: Progression was detected in 43.6% of eyes with the higher-frequency data. Progression was detected in 34.2% of eyes with the lower-frequency data. The higher-frequency series was about 69% more likely to identify progression using the mean deviation analysis. Using a point-by-point analysis, progression was detected in 39.5% of eyes with higher-frequency data versus 35.7% with lower-frequency data. The higher-frequency series was still more likely to detect progression, although the difference was smaller. Advanced Glaucoma Intervention Study frequency analysis This is important, but it must be interpreted correctly. The study showed that more frequent testing detects statistical progression sooner. It did not show that the additional tests themselves slowed disease or preserved vision. It was also not a randomized trial of two separate monitoring programs; the lower-frequency series was created by deleting tests from an existing dataset. Six-monthly testing may be a practical compromise A longitudinal cohort study used data from 1,072 eyes of 665 patients to model how quickly different rates of glaucoma progression could be detected. For eyes losing approximately 2 decibels per year, a progression signal could be detected with 80% statistical power after approximately: 3.3 years with yearly testing 2.4 years with testing twice per year 2.1 years with testing three times per year For slower loss of approximately 0.5 decibels per year, detection took approximately: 7.3 years with yearly testing 5.7 years with twice-yearly testing 5.0 years with testing three times per year The improvement from yearly to twice-yearly testing was larger than the improvement from twice-yearly to three-times-yearly testing. The authors concluded that two reliable baseline tests followed by testing approximately every six months, with confirmation of suspected progression, may offer a practical balance between speed and burden. Longitudinal cohort study of visual field testing frequency Personalized schedules may be more efficient than fixed schedules A separate analysis using data from the Advanced Glaucoma Intervention Study and the Collaborative Initial Glaucoma Treatment Study evaluated a personalized testing model. The model increased testing when the patient’s previous results suggested a higher likelihood of progression and reduced testing when the disease appeared stable. Compared with a fixed yearly schedule, the model: Detected progression 57% sooner. Improved progression-detection efficiency by 29%. Did not require more visual field tests overall. This was a model based on previous clinical trial data rather than a prospective implementation study. It supports a risk-based approach, rather than testing every patient at the same frequency. Personalized glaucoma monitoring schedule study Frontloading tests may increase information without adding visits An emerging clinic-based strategy is to perform two visual field tests per eye during the same visit and use their average. A 2025 prospective study found that this “frontloaded” approach reduced variability in global and point-by-point measurements compared with using one test per visit. The average rate of progression was similar, but the estimates were more precise. Frontloaded visual field testing study This may be useful for patients who cannot perform home testing or who have difficulty attending additional appointments. Do More Tests Lead to More Treatment Changes? The clinical pathway A confirmed visual field decline may lead an eye specialist t Support the show

    Real-World Evidence: Outcomes When Testing Frequency Increases

  3. 3d ago

    Oxidative Stress Pathways from High Sugar Exposure: Nrf2, Mitochondria, and RGC Survival

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/oxidative-stress-pathways-from-high-sugar-exposure-nrf2-mitochondria-and-rgc-survival Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Oxidative Stress Pathways from High Sugar Exposure: Nrf2, Mitochondria, and Retinal Ganglion Cell Survival Introduction High sugar exposure is often discussed as though it has one simple effect on the eye. The biology is more complicated. In experimental studies, elevated D-glucose can increase reactive oxygen species, disrupt mitochondrial energy production, alter antioxidant defenses, activate retinal glial cells, and promote retinal ganglion cell injury. Most of the evidence comes from two types of research: Cell-culture studies, in which retinal cells are exposed to glucose concentrations commonly ranging from 20 to 40 millimoles per liter, sometimes for several days. Diabetic animal models, in which chronic hyperglycemia occurs together with vascular dysfunction, inflammation, lipid abnormalities, advanced glycation products, and tissue hypoxia. These models do not prove that one high-sugar meal directly kills retinal ganglion cells. They do, however, support a biological pathway in which persistent or repeated hyperglycemia increases oxidative pressure and reduces the ability of ocular cells to recover. The most consistent model is: > High glucose → increased reactive oxygen and nitrogen species → mitochondrial stress and impaired energy production → inadequate nuclear factor erythroid 2-related factor 2 antioxidant activity → inflammation, glial reactivity, and retinal ganglion cell apoptosis. The strength of each link varies by cell type, glucose concentration, exposure time, and whether the experiment involves diabetes, glaucoma-related stress, or isolated high glucose. --- The central redox system: reactive oxygen species and nuclear factor erythroid 2-related factor 2 Reactive oxygen species are chemically reactive oxygen-containing molecules. In small amounts, they participate in normal cell signaling. When their production exceeds antioxidant capacity, they can oxidize proteins, membrane lipids, mitochondrial DNA, and other cellular structures. The main protective pathway discussed in this context is controlled by nuclear factor erythroid 2-related factor 2, commonly called Nrf2. Under resting conditions, Nrf2 is held in the cytoplasm by Kelch-like ECH-associated protein 1, or Keap1, which promotes its degradation. When oxidative stress is sensed, Nrf2 can stabilize, move into the nucleus, and stimulate antioxidant-response genes. These include genes involved in glutathione production, superoxide removal, hydrogen peroxide breakdown, thioredoxin recycling, and detoxification. () Important Nrf2-regulated defenses in retinal cells include: Glutamate-cysteine ligase, which supports glutathione production Superoxide dismutase 2, a mitochondrial antioxidant enzyme Catalase Thioredoxin Heme oxygenase-1 NAD(P)H quinone oxidoreductase 1 A key finding across the literature is that high glucose does not always completely turn off Nrf2. Instead, the response may be delayed, transient, cell-specific, or insufficient for the amount of oxidative stress produced. --- How high glucose increases oxidative stress in ocular cells Increased metabolic pressure Retinal neurons and glial cells are metabolically active. When excess glucose enters the cell, more carbon is directed through glycolysis and mitochondrial energy pathways. This can increase the supply of reducing equivalents to the mitochondrial respiratory chain. If electron transport becomes overloaded or poorly coordinated, electrons can leak and generate superoxide. Experimental retinal studies have also identified non-mitochondrial contributors, including: Activation of nicotinamide adenine dinucleotide phosphate oxidase Increased inflammatory signaling through nuclear factor kappa B Thioredoxin-interacting protein induction Nitric oxide and reactive nitrogen species production Disruption of glutathione and antioxidant enzyme systems In Müller glial cells, high glucose increased reactive oxygen species within hours and increased reactive nitrogen species even earlier. The same study found increased nuclear factor kappa B signaling and increased inducible nitric oxide synthase, linking redox imbalance to inflammation. () Oxidative stress can become self-reinforcing Mitochondria are both a source and a target of reactive oxygen species. Once mitochondrial proteins, membranes, or mitochondrial DNA are damaged, the respiratory chain may become less efficient. This can produce still more oxidant leakage, creating a feedback loop: > High glucose → mitochondrial stress → more reactive oxygen species → further mitochondrial damage. In Müller cells, high glucose increased mitochondrial superoxide, disrupted mitochondrial membrane potential, and increased the mitochondrial localization of thioredoxin-interacting protein. These changes were associated with mitochondrial dysfunction and impaired mitochondrial quality control. () --- Evidence for glucose-induced mitochondrial dysfunction Müller glial cells One of the clearest mitochondrial studies used a rat Müller cell line exposed to 30 millimoles per liter glucose for seven days. High glucose caused: Mitochondrial fragmentation Greater variation in mitochondrial membrane potential Lower basal and maximal oxygen consumption Lower extracellular acidification Cytochrome c release Increased apoptosis These findings are important because they connect mitochondrial structural changes with functional failure and cell death rather than merely showing an increase in a laboratory oxidative-stress marker. () A related study found that high glucose increased thioredoxin-interacting protein, mitochondrial superoxide, and mitochondrial membrane-potential abnormalities in rat Müller cells. The changes were accompanied by impaired mitophagy, the process that removes damaged mitochondria. () More recent work suggests that mitochondrial remodeling is not always the same in every stage of disease. Under diabetic conditions, Müller cells may initially use mitochondrial fragmentation as an adaptive response to remove damaged segments. In more advanced neurodegeneration, mitochondrial hyperfusion and defective turnover may develop instead. This means that mitochondrial shape alone cannot be interpreted without considering exposure duration and disease stage. () Retinal ganglion cells Retinal ganglion cells are especially vulnerable to mitochondrial stress because they have long axons and substantial energy requirements. In high-glucose retinal ganglion cell models, investigators have reported: Increased reactive oxygen species Loss or abnormality of mitochondrial membrane potential Cytochrome c release Reduced antioxidant enzyme activity Increased B-cell lymphoma-2-associated X protein and caspase signaling Increased terminal deoxynucleotidyl transferase dUTP nick-end labeling, a marker of DNA fragmentation Reduced cell survival In one study, L-carnitine, a mitochondrial-supporting molecule, reduced glucose-induced reactive oxygen species and lipid peroxidation. It also restored mitochondrial membrane potential, reduced cytochrome c release, lowered caspase-9 and caspase-3 activation, and shifted the B-cell lymphoma-2-associated X protein to B-cell lymphoma-2 balance toward cell survival. () A 2024 study using a retinal precursor cell model and diabetic mice found that high glucose or diabetes was associated with mitochondrial dysfunction, reactive oxygen species production, abnormal antioxidant protein expression, and retinal ganglion cell apoptosis. Increasing DJ-1, a protein involved in mitochondrial protection and redox control, improved mitochondrial function and reduced oxidative injury. () Mitochondrial DNA damage Mitochondrial DNA is located close to the respiratory chain and has less protection than nuclear DNA. A recent retinal ganglion cell study reported that high glucose was associated with mitochondrial structural abnormalities, increased reactive oxygen species, abnormal mitochondrial membrane potential, lower oxygen consumption, lower adenosine triphosphate production, and mitochondrial DNA damage. The authors also observed reduced expression of proteins involved in DNA damage repair. () These results support a model in which mitochondrial damage is not simply a consequence of apoptosis. It may occur early enough to contribute to the decision of a retinal ganglion cell to enter an apoptotic pathway. --- Evidence for impaired or inadequate Nrf2 antioxidant responses A transient Nrf2 failure in Müller cells A detailed time-course study exposed primary rat Müller cells to 25 millimoles per liter glucose for one to 48 hours. The findings show why the phrase “Nrf2 impairment” needs to be used carefully: Reactive oxygen species increased from approximately 12 to 48 hours. Reactive nitrogen species rose earlier. Nrf2 protein and nuclear Nrf2 temporarily decreased after approximately three hours. Glutamate-cysteine ligase, superoxide dismutase 2, and thioredoxin messenger RNA fell during the early exposure period. Glutathione remained low even after some Nrf2 measures recovered. Nrf2 and several antioxidant genes increased later, suggesting a delayed compensatory response. Thus, high glucose produced an early window in which oxidative stress increased while the Nrf2 antioxidant program was temp Support the show

    Oxidative Stress Pathways from High Sugar Exposure: Nrf2, Mitochondria, and RGC Survival

  4. 4d ago

    Aspartame, Sucralose, Saccharin, and Stevia: Comparative Mechanistic Plausibility in Glaucoma

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/aspartame-sucralose-saccharin-and-stevia-comparative-mechanistic-plausibility-in-glaucoma Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Aspartame, Sucralose, Saccharin, and Stevia: Comparative Mechanistic Plausibility in Glaucoma Introduction People with glaucoma often ask whether diet drinks, artificial sweeteners, or stevia could damage the optic nerve. The question is biologically reasonable because glaucoma is not only an eye-pressure disorder. Retinal ganglion cell injury can also involve vascular dysregulation, impaired endothelial function, oxidative stress, mitochondrial dysfunction, blood-retinal barrier changes, and chronic neuroinflammation. () However, a biologically plausible pathway is not the same as a demonstrated clinical risk. At present, there is no established human evidence that ordinary consumption of aspartame, sucralose, saccharin, or purified steviol glycosides causes glaucoma or accelerates glaucomatous progression. The available evidence is mainly regulatory toxicology, absorption studies, metabolic research, cell experiments, animal studies, and research on cardiovascular or inflammatory outcomes rather than glaucoma itself. Existing glaucoma nutrition reviews do not identify these sweeteners as proven glaucoma risk factors. () The most defensible conclusion is therefore: > For typical intake within established safety limits, all four sweeteners are more likely to be neutral with respect to glaucoma than directly harmful or beneficial. The main potential benefit is indirect: replacing sugar-sweetened foods or beverages may reduce glucose-related vascular stress. The main uncertainty concerns high, chronic intake and individual metabolic or microbiome responses—not a proven direct toxic effect on the optic nerve. How glaucoma physiology relates to sweeteners Glaucoma involves progressive loss of retinal ganglion cells and their optic nerve axons. Elevated intraocular pressure is the most important modifiable risk factor, but some patients continue to lose retinal tissue even when pressure is adequately controlled. This has led to increased interest in blood flow, endothelial function, mitochondrial injury, and immune signaling. () Endothelial function and ocular blood flow The vascular endothelium regulates vessel tone, blood flow, permeability, inflammation, and nitric oxide signaling. Studies of primary open-angle glaucoma have reported systemic vascular abnormalities, including impaired peripheral endothelial function and possible involvement of nitric oxide-related pathways. These observations are particularly relevant to normal-tension glaucoma and other forms in which optic nerve injury occurs at relatively modest eye pressures. () Still, brachial artery flow-mediated dilation is not the same as blood flow at the optic nerve head. A change in systemic vascular function does not automatically cause a change in ocular perfusion, and a laboratory effect on endothelial cells does not establish glaucoma risk. Neuroinflammation and the retinal immune environment The retina contains resident immune cells called microglia, along with astrocytes and Müller cells. Under chronic stress, these cells can release inflammatory mediators such as tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, complement-related proteins, and other signaling molecules. Persistent glial activation may amplify retinal ganglion cell injury. () The blood-retinal barrier normally limits exposure of retinal tissue to circulating substances and inflammatory cells. Barrier disruption can increase vascular leakage and create a more inflammatory environment, but evidence that dietary sweeteners disrupt this barrier in living human eyes is currently lacking. () Basic pharmacology of the four sweeteners For the full table, please open this article on visualfieldtest.com. The United States Food and Drug Administration lists the thresholds above and distinguishes high-purity steviol glycosides from crude stevia leaf products. The World Health Organization Joint Food and Agriculture Organization/World Health Organization Expert Committee on Food Additives uses a lower aspartame threshold of 40 milligrams per kilogram per day, while its table for saccharin, sucralose, and steviol glycosides lists 15, 5, and 4 milligrams per kilogram per day, respectively. () Aspartame Absorption and metabolism Aspartame is a small methyl ester made from two amino acids. It is rapidly broken down in the digestive tract into: Phenylalanine Aspartic acid Methanol The Joint Food and Agriculture Organization/World Health Organization Expert Committee on Food Additives concluded that intact aspartame does not enter the systemic circulation in meaningful amounts. Its metabolites are the same or chemically similar to substances obtained from ordinary foods. () This is important for glaucoma risk assessment. A cell experiment in which retinal neurons are exposed directly to aspartame does not reproduce ordinary human exposure if intact aspartame is absent from the blood. The biologically relevant question would be whether phenylalanine, aspartic acid, methanol, or their downstream products reach the retina at harmful concentrations. People with phenylketonuria, a rare inherited disorder of phenylalanine metabolism, should avoid or strictly limit aspartame according to medical guidance. This is a specific metabolic condition, not evidence that ordinary aspartame intake causes glaucoma in the general population. () Endothelial effects Direct human studies linking aspartame with impaired vascular endothelial function are limited. In one laboratory model using glomerular microvascular endothelial cells, aspartame did not reduce cell viability and, at selected concentrations, helped reduce vascular leakage caused by vascular endothelial growth factor. This finding should not be interpreted as an eye benefit: the cells were kidney-derived, the experiment was performed outside the body, and the vascular stimulus was artificial. () The more clinically relevant comparison is with sugar. Sugar-sweetened beverages can cause acute glucose elevations that increase oxidative stress and impair systemic endothelial function. Replacing those beverages with a noncaloric option may therefore reduce vascular stress, even if the sweetener itself has no special protective effect. () Neuroinflammatory and retinal signals Animal studies have reported oxidative stress, inflammatory signaling, and changes in brain tissue after relatively high or prolonged aspartame exposure. Findings have included increased tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, nuclear factor kappa B signaling, inducible nitric oxide synthase, and glial fibrillary acidic protein. These findings demonstrate biological activity in experimental models, but they do not show that ordinary human intake damages retinal ganglion cells. () A recent retinal study is mechanistically interesting because aspartame increased intracellular calcium in isolated rat retinal neurons, and saccharin produced a similar effect. Excessive intracellular calcium can contribute to neuronal injury in several neurodegenerative diseases. However, the experiment used isolated retinal cells exposed directly to sweeteners, not living animals with glaucoma, and direct exposure to intact aspartame does not mirror its normal human pharmacokinetics. () Overall assessment of aspartame Potential harm: Biologically plausible only in a limited, indirect sense. High-dose animal studies and isolated retinal-cell findings justify continued research but do not establish a dietary glaucoma hazard. Potential benefit: Possible when used instead of sugar-sweetened beverages, particularly if it lowers total sugar intake. Most likely interpretation at ordinary intake: Neutral with respect to glaucoma, provided the person does not have phenylketonuria and intake remains within established limits. Sucralose Absorption and metabolism Sucralose is a chlorinated derivative of sucrose. It is approximately 600 times sweeter than sugar, allowing very small quantities to provide sweetness. In a human pharmacokinetic study, approximately 78 percent of a radiolabeled dose was recovered in feces and approximately 14.5 percent in urine. The material in feces was essentially unchanged sucralose. Most urinary material was also sucralose, with only a small fraction represented by more polar, probably conjugated metabolites. () This means that sucralose is not simply “inert,” but it is also not extensively metabolized into large quantities of reactive compounds. Its strongest potential biological pathway may be through intestinal taste receptors, gut microbial interactions, and metabolic signaling, rather than direct delivery to retinal tissue. Endothelial effects The available human vascular evidence does not show a consistent direct endothelial injury signal. An acute study found that sucralose did not alter brachial artery flow-mediated dilation, and another study in older adults found no acute effect of intestinal sucralose administration on blood pressure or superior mesenteric artery blood flow. These studies were small and short-term, but they do not support a strong immediate vascular toxicity signal. () In a laboratory model of glomerular endothelial cells, sucralose reduced vascular leakage caused by vascular endothe Support the show

    Aspartame, Sucralose, Saccharin, and Stevia: Comparative Mechanistic Plausibility in Glaucoma

  5. 6d ago

    Does Dietary Sugar Intake Increase Glaucoma Risk? A Systematic Review and Meta-analysis Blueprint

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/does-dietary-sugar-intake-increase-glaucoma-risk-a-systematic-review-and-meta-analysis-blueprint Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Does Dietary Sugar Intake Increase Glaucoma Risk? A Systematic Review and Meta-analysis Blueprint Introduction Whether dietary sugar contributes to glaucoma risk remains uncertain. The available research is limited and does not consistently measure added sugar itself. Some studies have examined total carbohydrate intake, low-carbohydrate dietary patterns, processed sweets, or ultra-processed foods instead. For example, a prospective Spanish cohort found that participants with the highest total carbohydrate intake had a higher risk of newly diagnosed glaucoma, although no individual carbohydrate food group was clearly responsible. () In contrast, a large analysis of three United States cohorts found no clear association between overall low-carbohydrate dietary scores and primary open-angle glaucoma, although a vegetable-based low-carbohydrate pattern showed a possible association with a specific visual field-loss subtype. () A small case-control study also reported that patients with primary open-angle glaucoma consumed more sweets containing processed sugar than controls, but its retrospective design leaves substantial potential for recall bias and residual confounding. () A 2024 scoping review concluded that most glaucoma nutrition studies relied on food frequency questionnaires and that only a small number of prospective studies had examined carbohydrate-related exposures. () This protocol is designed to determine whether total sugar, added sugar, free sugar, sugary beverages, total carbohydrate, glycemic load, or glycemic index are associated with: Incident primary open-angle glaucoma Change in intraocular pressure Retinal nerve fiber layer loss or glaucoma progression The review should estimate associations carefully without implying that sugar causes glaucoma. Dietary studies are vulnerable to measurement error, confounding, reverse causation, and differences in glaucoma diagnosis. --- Review Objective and Research Question Primary research question Among adults, is higher habitual intake of dietary sugar or sugar-related exposures associated with a greater risk of developing glaucoma or experiencing glaucoma-related structural or pressure changes? Secondary research questions The review should determine: Whether associations differ between added sugar, total sugar, free sugar, and sugar-sweetened beverages Whether glycemic load or glycemic index shows a stronger relationship than sugar grams alone Whether associations differ according to baseline diabetes status Whether findings differ between primary open-angle glaucoma, normal-tension glaucoma, high-tension glaucoma, exfoliative glaucoma, pigmentary glaucoma, and primary angle-closure glaucoma Whether associations are stronger for glaucoma incidence or for disease progression How much results are affected by adjustment for diabetes, body mass index, blood pressure, and total energy intake Whether food frequency questionnaire measurement error may have weakened or distorted reported associations Prespecified causal estimands Because diabetes, body mass index, blood pressure, and total energy intake may play different roles in the causal pathway, the review should distinguish between two related but different questions: Total dietary association: Does a higher sugar exposure relate to glaucoma risk through all plausible pathways, including pathways involving weight gain, diabetes, blood pressure, and vascular or metabolic changes? Metabolic-independent association: Does sugar remain associated with glaucoma after adjustment for diabetes, body mass index, and blood pressure? The second estimate should not be described as the total effect of sugar. It is better described as a conditional or metabolically adjusted association, because adjustment may remove part of the pathway through which diet could influence eye health. --- Eligibility Criteria Population Include studies of: Human adults aged 18 years or older General population samples Occupational or community-based cohorts Patients with ocular hypertension or established glaucoma Participants with or without diabetes Studies involving children may be included in a separate exploratory analysis if sufficient evidence exists, but they should not be pooled with adult studies. Eligible study designs Include: Prospective cohort studies Longitudinal population-based studies Nested case-control studies within prospective cohorts Case-control studies in which dietary exposure was assessed for a period before glaucoma diagnosis or progression Retrospective analyses only if dietary exposure clearly preceded the outcome and the study provides usable effect estimates Prospective studies should be the main evidence base for incidence and progression. Case-control studies should be synthesized separately because their exposure measurement is more vulnerable to recall and selection bias. Required exposure timing The exposure must be measured: Before glaucoma diagnosis Before the progression period being studied Or repeatedly during follow-up in a way that permits a time-ordered analysis Studies measuring diet and glaucoma at the same visit should be excluded from the primary quantitative synthesis because they cannot establish whether dietary exposure preceded the disease. They may be retained for narrative context. Required outcome information Studies must report at least one of the following: Incident glaucoma Change in intraocular pressure Retinal nerve fiber layer loss Glaucoma progression Visual field progression Optic nerve or neuroretinal rim progression Studies must provide a relative risk, hazard ratio, odds ratio, mean difference, annualized rate of change, or enough data to calculate one. Exclude Exclude: Animal or laboratory studies Ecological studies Case reports and case series Studies of blood glucose or glycated hemoglobin without a dietary exposure Studies focused only on diabetic retinopathy Studies that do not distinguish glaucoma from nonspecific visual impairment Studies in which the dietary exposure is a nutritional supplement rather than food or beverage intake Duplicate reports from the same cohort, unless they provide non-overlapping exposure or outcome data If several publications use the same cohort, select the report with the longest follow-up or the most complete outcome ascertainment. Additional reports may be used for subtype or progression analyses without counting participants twice. --- Exposure Definitions Sugar-related exposures must not be treated as interchangeable. The protocol should extract each exposure separately and avoid pooling them unless the definitions are sufficiently comparable. Exposure classification table For the full table, please open this article on visualfieldtest.com. The United States Food and Drug Administration distinguishes total sugars from added sugars: total sugars include sugars naturally present in foods such as fruit and milk, whereas added sugars are incorporated during processing or preparation. () The World Health Organization defines free sugars more broadly to include added sugars and sugars naturally present in honey, syrups, fruit juice, and fruit juice concentrate, while excluding the sugars naturally present in intact fruit, vegetables, and milk. () Sugar-sweetened beverages Sugar-sweetened beverages should be analyzed separately from solid foods because they: Are often consumed quickly May produce a high glycemic exposure Usually provide few or no grams of fiber May be associated with total energy intake and weight gain Can be measured more reliably in some questionnaires than total added sugar Diet beverages should not be combined with sugar-sweetened beverages. They should be analyzed separately as an exploratory exposure because people who choose artificially sweetened drinks may differ systematically from people who do not. One hundred percent fruit juice should also be analyzed separately. It should not automatically be classified as equivalent to either a sugar-sweetened beverage or intact fruit. Glycemic load For studies providing sufficient information, glycemic load should be calculated or extracted as: > Glycemic load = glycemic index × grams of available carbohydrate per serving ÷ 100 Glycemic load reflects both the quality and quantity of carbohydrate. Glycemic index reflects the relative glucose response to a carbohydrate-containing food, whereas glycemic load also accounts for the amount consumed. () Total carbohydrate, glycemic load, and added sugar should not be pooled into a single exposure category. A diet may contain a large amount of carbohydrate from whole grains or legumes but relatively little added sugar. Exposure timing Extract whether exposure was measured: At baseline only As a cumulative average of repeated questionnaires As the most recent diet measure As a change from baseline Using a lagged exposure, such as diet measured two or more years before diagnosis Repeated and cumulative dietary measures should be preferred for chronic outcomes when available because a single questionnaire may not represent long-term dietary habits. --- Outcome Definitions 4.1 Incident primary open-angle glaucoma The primary incidence outcome should be newly diagnose Support the show

    Does Dietary Sugar Intake Increase Glaucoma Risk? A Systematic Review and Meta-analysis Blueprint

  6. 6d ago

    Global Eye Health 2026: Tackling Glaucoma Disparities

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/global-eye-health-2026-tackling-glaucoma-disparities Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Global Eye Health 2026: Tackling Glaucoma Disparities Evidence reviewed through June 30, 2026 Glaucoma is often called a “silent thief of sight” because it can damage the optic nerve for years before a person notices a problem. Once vision is lost, it usually cannot be restored. However, early detection, pressure-lowering treatment, laser therapy, and surgery can often slow or stop further damage. The global glaucoma challenge is therefore not simply a lack of effective treatments. It is a problem of late detection, unequal access, medicine cost, weak referral systems, limited surgical capacity, and difficulty maintaining lifelong care. These problems are most severe in low-resource settings, rural communities, and groups facing financial or gender-related barriers. The global glaucoma burden in 2026 There is no single real-time worldwide glaucoma census. Different studies measure different outcomes: Total glaucoma disease includes people with early disease who may have no symptoms. Glaucoma-related blindness counts people whose glaucoma has caused profound vision loss. Disability-adjusted life years measure the combined effect of disability and premature loss of healthy life. These measures should not be treated as interchangeable. For the full table, please open this article on visualfieldtest.com. The long-standing global projection of 76 million people with glaucoma in 2020 and 111.8 million by 2040 comes from a systematic review of population eye studies. The 2024 global analysis of glaucoma-related vision loss estimated 3.61 million people were blind and 4.14 million had moderate-to-severe vision impairment because of glaucoma in 2020. () A study published online in June 2026 using Global Burden of Disease 2021 data found that the absolute number of modelled glaucoma cases increased by approximately 86% between 1990 and 2021, even though age-standardised prevalence and disability-adjusted life-year rates declined. Population growth and ageing explain much of this apparent contradiction: the risk at a given age may be falling, but more people are reaching the ages when glaucoma becomes common. () Regional disparities are marked Sub-Saharan Africa: high disease burden and late presentation Sub-Saharan Africa continues to experience the highest age-standardised burden of glaucoma-related blindness and moderate-to-severe vision impairment. In the 2020 global analysis, the age-standardised prevalence of glaucoma-related blindness among people aged 50 years and older was approximately 0.66% in Sub-Saharan Africa, compared with 0.20% globally. The region also had the highest age-standardised prevalence of glaucoma-related moderate-to-severe vision impairment. () A 2025 systematic review and Bayesian meta-analysis estimated glaucoma prevalence in Africa at 5.59%, with primary open-angle glaucoma accounting for approximately 5.07%. The pooled prevalence was highest in Southern Africa and lowest in East Africa, although the authors noted substantial variation between countries and studies. () Nigeria illustrates the scale of the problem. A national population survey estimated glaucoma prevalence at approximately 5.02% among people aged 40 years and older. In clinical and outreach settings, many people present after substantial damage has already occurred. These findings should not be interpreted as evidence that every Nigerian patient is diagnosed late, but they demonstrate the consequences of limited case detection and weak access to continuing care. () The problem is intensified by workforce distribution. A review of glaucoma needs among people of African descent reported that most ophthalmologists in Africa work in urban centres while much of the population lives in rural areas. It also cited estimates that approximately 90% of people with glaucoma in Africa may be unaware that they have the disease, although this figure comes from older and heterogeneous sources and should be interpreted cautiously. () Asia: large absolute numbers and angle-closure risk Asia contains a large share of the global population and therefore carries a substantial absolute glaucoma burden even where prevalence rates are lower than those reported in parts of Africa. The pattern of glaucoma also differs. Primary angle-closure glaucoma is more common in many East and Southeast Asian populations than in people of European ancestry. It can cause rapid and severe visual loss, particularly when an acute pressure crisis occurs. Primary open-angle glaucoma remains important throughout Asia, especially as populations age. () In younger regions of South and Southeast Asia, glaucoma may represent a smaller proportion of all blindness because cataract and other conditions remain more common. This does not mean the glaucoma burden is small. As life expectancy rises, the number of people needing long-term glaucoma monitoring is expected to increase. Europe and North America: better access, but underdiagnosis remains common High-income health systems generally have more ophthalmologists, diagnostic equipment, medicines, and insurance coverage. Yet they have not eliminated the detection gap. A 2025 analysis of 55,415 participants from seven European countries estimated glaucoma prevalence at 2.99% among adults aged 40 years and older. More than half of cases, 56.4%, had not previously been diagnosed. In people younger than 50 years, the proportion of undiagnosed disease exceeded 80%. Applying these estimates to the European population produced an estimate of 12.26 million people with glaucoma in 2024, including 6.86 million who were undiagnosed. () High-income countries had the highest proportion of blindness attributed to glaucoma in the 2020 global analysis—approximately 26%. This does not mean that high-income countries had the highest glaucoma blindness rate. Rather, cataract and other treatable causes of blindness are more often managed, leaving glaucoma as a larger share of the remaining blindness burden. () The Caribbean and African-descended populations People of African descent, including African-Caribbean populations, have a higher risk of primary open-angle glaucoma and may develop it at younger ages. The disease may also progress more aggressively in some patients. Barbados and several other Caribbean countries have reported a particularly high contribution of glaucoma to blindness. () These risks interact with social conditions. High medicine prices, missed appointments, limited surgical capacity, and mistrust after poor surgical experiences can produce severe disease even where specialist services technically exist. Why people are missed or untreated Glaucoma is usually asymptomatic early Early glaucoma often causes no pain and does not noticeably reduce central vision. People may continue reading, working, and driving while peripheral vision is gradually lost. This makes glaucoma different from conditions that encourage people to seek care quickly. A person may not feel an immediate benefit from eye drops, while side effects, inconvenience, and cost occur every day. This is one reason why diagnosis alone is not enough: patients must be able to start, continue, and monitor treatment. For this reason, the most practical approach is usually targeted case-finding followed by confirmatory assessment, rather than referring every person with one abnormal screening measurement directly into lifelong treatment. National Institute for Health and Care Excellence guidance describes a two-stage assessment in which an initial abnormal result is confirmed through a more detailed examination. () Affordability affects every stage of care The cost of glaucoma care includes more than the price of an eye drop. Patients may need to pay for: Transport to a clinic Several diagnostic tests Repeated visits Medicines for the rest of their lives Time away from work or caregiving Surgery and postoperative reviews Travel to a distant referral hospital A worldwide comparison of glaucoma treatment prices found that affordability varied greatly by country and household income. Timolol was generally the least expensive medicine, but the overall cost of treatment, laser, and surgery could still be substantial relative to household income in lower-income countries. () A 2024 Ghanaian cost-of-illness study found an average patient cost of approximately 60.78 United States dollars for glaucoma management. Direct costs accounted for about 94% of the total, with medicines responsible for 42% and laboratory or diagnostic services for 26%. Some patients paid out of pocket for timolol even though they expected it to be covered by the national insurance system. () These findings support a shift from isolated fee waivers to broader financial protection: essential medicines, diagnostic testing, transport support, and surgery all need to be considered. Adherence is a health-system issue, not simply a patient issue Common barriers to using glaucoma medicines include: Forgetting doses Difficulty putting drops into the eye Poor vision or arthritis that makes bottle handling difficult Complex schedules involving several medicines Eye irritation and other side effects Lack of understanding about an asymptomatic disease Medicine shortages Long travel distances to pharmacies or clinics Cost and insurance restrictions Support the show

    Global Eye Health 2026: Tackling Glaucoma Disparities

  7. Jul 26

    Glaucoma and High Myopia: Mid-2026 Clinical Insights

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/glaucoma-and-high-myopia-mid-2026-clinical-insights Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Glaucoma and High Myopia: Mid-2026 Clinical Insights Evidence reviewed through July 26, 2026. Introduction High myopia and glaucoma often overlap, but they are not the same condition. High myopia changes the shape of the eye, optic nerve, retina, and supporting tissues. These changes can imitate glaucoma on an eye examination, optical coherence tomography, or visual field test. At the same time, high myopia appears to increase the eye’s susceptibility to true glaucomatous damage. High myopia is commonly defined as a spherical equivalent refractive error of −6 diopters or more negative or an axial length of approximately 26 millimeters or longer, although definitions vary between studies. The distinction matters because a highly myopic eye may have an abnormal-looking optic disc and visual field without progressive glaucoma, while another eye may develop glaucoma despite apparently normal eye pressure. Evaluating glaucoma in myopic eyes Interpreting the structure–function relationship in high myopia-associated glaucoma () The most reliable principle through mid-2026 is: > Do not diagnose or exclude glaucoma from one “red” optical coherence tomography result, one tilted disc, one unusual visual field, or one eye-pressure reading. Look for reproducible, anatomically coherent change over time. Why the Glaucoma–Myopia Interface Is Difficult Axial elongation stretches and remodels the back of the eye. The optic disc may become tilted, rotated, enlarged, or obliquely inserted. The surrounding tissue may show a large temporal crescent, peripapillary atrophy, a gamma zone, posterior staphyloma, or other myopic changes. These findings can: Make the optic cup appear larger than it truly is. Shift the normal location of retinal nerve fiber layer bundles. Cause false-positive color warnings on optical coherence tomography. Create visual field defects that resemble nasal steps or arcuate defects. Make the same retinal location appear different on serial scans if the scan is not centered consistently. Hide early central or paracentral glaucoma damage when only a standard 24-2 visual field is used. The 2026 European Glaucoma Society research-priority survey found that the most common questions from glaucoma specialists concerned how to distinguish myopic structural change from glaucomatous damage and progression, followed by the reliability of optical coherence tomography and visual field testing. This indicates that the problem remains clinically unresolved even among specialists. Research priorities for diagnostics, progression monitoring, and treatment of glaucoma in myopic eyes () Optical Coherence Tomography: Recognizing Myopia-Related Artifacts Why a normal optical coherence tomography report may be misleading Most commercial optical coherence tomography devices compare a patient’s measurements with a normative database. These databases may contain relatively few highly myopic eyes. As a result, a healthy myopic eye may be incorrectly labeled as having abnormally thin retinal nerve fiber tissue. Long axial length also creates ocular magnification. A scan circle designed to be a fixed size may actually be placed farther from the optic disc than intended. Retinal nerve fiber tissue is naturally thinner farther from the disc, which can produce an artificially low measurement. In addition, myopic retinal anatomy can cause the scan to cross: Peripapillary atrophy. Posterior staphyloma. Peripapillary intrachoroidal cavitation. Retinoschisis or epiretinal membrane. Areas where the automated software cannot correctly identify the retinal boundaries. How common are artifacts? In one study, optical coherence tomography artifacts were found in approximately 51.9% of scans from highly myopic eyes, compared with 18.6% in eyes without high myopia. Peripapillary atrophy was a leading cause of artifact in highly myopic eyes. The frequency was even higher when high myopia and glaucoma were both present. The prevalence of optical coherence tomography artifacts in high myopia and its influence on glaucoma diagnosis () This does not mean optical coherence tomography is useless. It means the individual scan must be inspected rather than relying only on the summary page. A practical optical coherence tomography quality check Before interpreting a thickness map, the clinician should review: The raw cross-sectional images rather than only the color-coded report. The automated segmentation lines to confirm that they follow the correct retinal layers. The scan centration in relation to the optic disc, Bruch’s membrane opening, and fovea. Signal strength and motion artifacts. Whether the scan passes through peripapillary atrophy or a posterior staphyloma. Whether the same device, scan pattern, and positioning were used at each visit. Whether the apparent change is visible on the actual image or exists only in the software’s color classification. A new “red” sector is much less convincing when it is caused by segmentation failure, scan displacement, or a pre-existing tilted disc. Which optical coherence tomography measurements may help? Several approaches may improve confidence: Macular ganglion cell-inner plexiform layer or ganglion cell complex measurements. These may show better diagnostic performance than standard peripapillary retinal nerve fiber layer measurements in some highly myopic eyes. Bruch’s membrane opening minimum rim width. This measures the minimum rim tissue from the anatomic opening of Bruch’s membrane rather than relying only on the clinically visible disc margin. Anatomically corrected retinal nerve fiber layer scans. These attempt to account for axial length and the shifted position of nerve fiber bundles. Vertical, fovea-centered scans. These may improve structure–function matching when the usual peripapillary scan is distorted. Swept-source or wide-field imaging when posterior staphyloma, peripapillary cavitation, or a very large tilted disc makes conventional imaging difficult. A 2024 study found that macular ganglion cell-inner plexiform layer and peripapillary retinal nerve fiber layer parameters could still have good diagnostic accuracy in high axial myopia, but the results were population-specific and should not replace clinical examination or visual field testing. Diagnostic accuracy of optic nerve head and macula optical coherence tomography parameters Comparison of optical coherence tomography structural parameters for diagnosis of glaucoma in high myopia () Common optical coherence tomography traps For the full table, please open this article on visualfieldtest.com. Disc Tilt, Disc Rotation, and Peripapillary Anatomy What a tilted disc means A tilted disc is often associated with: An oval or vertically elongated disc. Oblique insertion of the optic nerve. Temporal peripapillary atrophy or a crescent. Rotation of the retinal nerve fiber layer pattern. Displacement of the central retinal vessels. A mismatch between the clinically visible disc margin and the true anatomic opening of Bruch’s membrane. A tilted disc does not prove glaucoma. However, it also does not protect the eye from glaucoma. The most concerning findings are not simply “tilt” or “cupping,” but focal, repeatable, progressive loss that corresponds to a visual field defect. Examples include: A focal inferior or superior rim notch. A wedge-shaped retinal nerve fiber layer defect. A disc hemorrhage. Corresponding loss in the macular ganglion cell-inner plexiform layer. A repeatable arcuate, nasal-step, or paracentral field defect. Why disc measurements can disagree In high myopia, the clinical disc margin, Bruch’s membrane opening, and anterior scleral canal opening may not line up. A 2025 prospective study found that highly myopic glaucoma eyes had larger Bruch’s membrane opening and anterior scleral canal opening areas, greater displacement between these structures, and a smaller neural canal minimum cross-sectional area than non-highly myopic glaucoma eyes. These anatomic features were associated with faster temporal visual field and retinal nerve fiber layer change over three years. High myopia-induced optic nerve head deformation and glaucoma progression () This supports a shift away from judging a myopic disc by cup-to-disc ratio alone. The important question is whether the nerve tissue is being lost in a pattern and at a rate consistent with glaucoma. Atypical Visual Field Patterns in High Myopia Visual field defects that may occur without glaucoma Highly myopic eyes can produce several unusual visual field patterns: Enlarged blind spot. Vertical step. Partial peripheral rim loss. Nonspecific or irregular depression. Mixed temporal and nasal loss. “Gourd-shaped” defects. Field loss associated with peripapillary atrophy, posterior staphyloma, or peripapillary intrachoroidal cavitation. A 2025 study found an enlarged blind spot in approximately 37% of eyes with nonpathologic high myopia. The enlarged blind spot was associated with a larger gamma zone, larger peripapillary hyperreflective ovoid mass-like structures, and other myopic anatomic findings. Enlarged blind spot linked to gamma zone and peripapillary hyperreflective ovoid mass-like structures () A standardized classification system separates high-myopia-related defects from glaucoma-like defects. Glaucoma-like patterns in Support the show

    Glaucoma and High Myopia: Mid-2026 Clinical Insights

  8. Jul 24

    Managing Glaucoma in Pregnancy 2026: Evidence and Consensus

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/managing-glaucoma-in-pregnancy-2026-evidence-and-consensus Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Managing Glaucoma in Pregnancy 2026: Evidence and Consensus Evidence cutoff: July 24, 2026 Pregnancy does not automatically make glaucoma treatment unsafe, and stopping glaucoma medication without medical supervision can permanently threaten vision. The goal is to protect the pregnant patient’s optic nerve while reducing avoidable exposure of the fetus or breastfed infant to glaucoma medicines. The best available evidence remains limited. There are no large randomized trials of glaucoma treatment during pregnancy. Current recommendations rely on medication labels, animal reproductive studies, pharmacokinetic research, retrospective case series, case reports, and expert consensus. The most current major guidance includes the 2026 American Academy of Ophthalmology Primary Open-Angle Glaucoma Preferred Practice Pattern, the American Glaucoma Society and Canadian Glaucoma Society practical guide, and updated clinical reviews. () > Important: This article is educational and cannot replace individualized care from a glaucoma specialist, obstetric clinician, and—when appropriate—a pediatric or neonatal clinician. Key recommendations at a glance Plan before conception whenever possible. Establish a target pressure, document the optic nerve and visual field, review medications, and consider laser treatment or surgery before pregnancy if glaucoma is advanced or difficult to control. Do not assume that pregnancy will lower pressure enough. Intraocular pressure often falls, but some patients with established glaucoma experience pressure elevation or visual field progression. Use the fewest medicines at the lowest effective exposure. Punctal occlusion and gentle eyelid closure should be used after every drop. Brimonidine is commonly preferred when a glaucoma drop is needed during pregnancy, but it should be stopped before delivery and avoided during breastfeeding because of possible infant central nervous system depression and apnea. Timolol may be used selectively, particularly when the maternal benefit is important, but fetal growth and heart rate should be considered, and newborns may require observation after late-pregnancy exposure. Topical carbonic anhydrase inhibitors such as dorzolamide or brinzolamide are possible alternatives when needed, although human pregnancy and milk data are limited. Oral acetazolamide is generally reserved for serious or refractory pressure elevation. It is often considered acceptable during breastfeeding, but exposure near delivery has occasionally been associated with temporary neonatal metabolic acidosis. Prostaglandin analogues are not first-line during pregnancy because of a theoretical risk of uterine contraction or premature labor and limited human data. Selective laser trabeculoplasty may reduce or eliminate medication exposure. Guidance differs slightly on first-trimester elective treatment, so timing should depend on disease severity and urgency. Incisional surgery is unusual but justified when vision is at meaningful risk. If it cannot be deferred, the second trimester is generally preferred, with local anesthesia and avoidance of antimetabolites whenever possible. How pregnancy changes intraocular pressure Normal physiologic changes Intraocular pressure usually decreases during pregnancy. Proposed explanations include: Increased aqueous humor outflow related to hormonal changes Reduced episcleral venous pressure Effects of progesterone and relaxin Pregnancy-related changes in blood chemistry and vascular physiology One study found that average intraocular pressure in the first trimester was approximately 2 millimeters of mercury higher than in the third trimester. Another study reported an approximately 19.6% reduction in women without ocular hypertension and a 24.4% reduction in women with ocular hypertension, although these studies were relatively small and older. () Pregnancy can also change corneal thickness and biomechanics, which may influence applanation pressure readings. For this reason, clinicians should interpret pressure trends together with the optic nerve, retinal nerve fiber layer imaging, and visual field—not pressure alone. In one review, both intraocular pressure and central corneal thickness had returned toward first-trimester values by approximately three months after delivery. () Why glaucoma can still worsen The average fall in pressure does not protect every patient. In a retrospective series of 28 eyes from 15 women with glaucoma: 57.1% had stable pressure without visual field progression. 17.9% developed visual field progression even though pressure was stable or increased. 17.9% developed pressure elevation without documented visual field progression. Two eyes had inconclusive data. Many patients required glaucoma medication during pregnancy. () The practical lesson is important: a lower pregnancy pressure does not prove that glaucoma is stable, and a normal-looking pressure does not exclude progression. Monitoring during pregnancy and after delivery Minimum monitoring At a minimum, a pregnant patient with established glaucoma should generally be assessed at least once during each trimester. This is a consensus-based recommendation rather than one supported by a large pregnancy trial. () A useful examination may include: Visual acuity Intraocular pressure using the same method when possible Optic nerve examination and photographs Visual field testing when the patient can perform it reliably Optical coherence tomography of the retinal nerve fiber layer and ganglion cell layer Gonioscopy when angle status is uncertain or angle closure is possible Medication review, adherence, and drop technique Heart rate and respiratory history if a beta-blocker is being used Practical monitoring intervals The following schedule is a practical risk-based framework, not a universally validated guideline: For the full table, please open this article on visualfieldtest.com. A visual field and structural baseline should ideally be obtained before conception. Repeating both tests once per trimester may be reasonable for moderate or advanced disease if the patient can tolerate testing, but excessive testing can create fatigue and unreliable results. Postpartum pressure rebound Pressure may rise again after delivery as pregnancy-related physiologic changes resolve. This may be especially important when medication was reduced or stopped during pregnancy. A postpartum plan should therefore be made before delivery rather than waiting for symptoms, because glaucoma progression is often silent. () Medication safety during pregnancy and breastfeeding A note about “pregnancy categories” Many older articles describe glaucoma medicines as Category B or Category C. The United States Food and Drug Administration replaced the former letter categories with descriptive pregnancy and lactation labeling in 2015. The older categories may still appear in reviews, but they should not be interpreted as modern, precise safety rankings. The current labeling emphasizes the quality of human data, animal findings, and the balance between maternal benefit and fetal or infant risk. () Medication comparison For the full table, please open this article on visualfieldtest.com. Brimonidine Brimonidine is frequently described as the preferred first medication during pregnancy because animal studies did not demonstrate fetal malformations at exposures substantially above typical ophthalmic exposure. However, current United States product labeling states that human pregnancy data are inadequate and that the medicine should be used only when the maternal benefit justifies potential fetal risk. () The more important issue is the newborn. Brimonidine crosses the blood-brain barrier and has been associated with central nervous system depression, excessive sleepiness, hypotension, bradycardia, and apnea in infants exposed directly to the medication. Animal studies also demonstrate transfer into milk. For this reason, the American Glaucoma Society handout and product labeling recommend stopping brimonidine before delivery and avoiding it during breastfeeding. () The precise stopping date is not established by high-quality evidence. A practical plan is to discontinue it well before expected delivery, with the exact timing based on disease severity, the alternative treatment, and obstetric and neonatal advice. There are a few reports of breastfeeding without apparent harm, but these involve very small numbers and sometimes multiple medications. LactMed therefore acknowledges the limited reassuring reports while also noting that manufacturers and many clinicians recommend avoiding brimonidine because the potential consequences in a newborn could be serious. () Timolol and other beta-blockers Topical timolol is systemically absorbed and can cross the placenta. Potential fetal or neonatal concerns include a slow heart rate and low blood pressure. Current clinical guidance supports selective use with the lowest effective exposure and consideration of fetal heart-rate and growth monitoring, especially with prolonged or late-pregnancy treatment. () The American Glaucoma Society has suggested that clinicians may consider reducing exposure—for example, using a lower concentration when clinically adequate—but patients should not change concentr Support the show

    Managing Glaucoma in Pregnancy 2026: Evidence and Consensus
See All (229)

Ratings & Reviews

About

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

Information

You Might Also Like